shutterstock_1263541591_igorgolovniov
IgorGolovniov / Shutterstock.com
25 April 2023AmericasLiz Hockley

Lawsuit against Celgene, BMS and others moves forward

New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
17 August 2023   Judges uphold PTAB decision invalidating Incept patents related to use of biodegradable filler in radiation treatment | Swedish firm Palette had challenged patents through inter partes review.
Americas
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.
Big Pharma
11 February 2021   Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.